The global leuprolide acetate market is expected to grow at a significant CAGR during the forecast period (2021-2027). The major factor contributing to the growth of the global leuprolide acetate market includes the rising prevalence of prostate cancer and uterine fibroid. According to the World Health Organization (WHO), in 2020, 10 million people died due to cancer, and prostate cancer accounted for the 1.41 million cases globally. According to the study published by Elsevier Ltd. on behalf of Reproductive Healthcare Ltd., in 2017, uterine fibroids are clinically apparent in only 40% of women aged 40 years and over. The incidence of leiomyomas is up to three-fold greater in black women.

Free Sample Copy @ https://www.omrglobal.com/request-sample/leuprolide-acetate-market

Leuprolide is a synthetic 9-residue peptide analog of gonadotropin-releasing hormone (GnRH). It is intended for the palliative treatment of prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. Leuprolide has a greater half-life as compared to the endogenous GnRH due to the single D-amino acid (D-leucyl) residue present in the structure. It acts by binding GnRH receptors and inducing downregulation of the sex steroids and gonadotropin hormone. There are several medications available for leuprolide including Eligard, Fensolvi, Lupaneta, Lupron, Viadur, Zeulide Depot, and others. The approved leuprolide was Lupon by Abbvie Endocrine Inc. in 1985.

A Full Report of Global Leuprolide Acetate Market is Available at:
https://www.omrglobal.com/industry-reports/leuprolide-acetate-market

The key players contributing to the growth of the global leuprolide acetate market by adopting various strategies such as product launches and developments, mergers and acquisition, partnerships, and agreements, include TOLMAR Pharmaceuticals, Varian Pharmed, avenit AG, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Livzon Pharmaceutical Group Co., Ltd., among others. For instance, in May 2021, Camcevi (leuprolide) by Foresee Pharmaceuticals received the US FDA approval for the treatment of patients with advanced prostate cancer. Camcevi is a ready-to-use subcutaneous depot formulation.

Global Leuprolide Acetate Market – Segmentation
By Product Type
Intramuscular Injection
Subcutaneous Injection
By Application
Prostate cancer
Precocious
Uterine fibroid
Others
By End-User
Hospitals
Clinic
Others

Global Leuprolide Acetate Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles
TOLMAR Pharmaceuticals
Varian Pharmed
Takeda Pharmaceutical Company Limited
Sun Pharmaceutical Industries Ltd.
Livzon Pharmaceutical Group Co. Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/leuprolide-acetate-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404